Stock Events

Stock Events

Protagonist Therapeutics 

$145.72
26
-$3.08-2.07% Friday 20:00
-$0.72-0.49%Friday 23:30After hours

Statistics

Day High
145.91
Day Low
145.43
52W High
160.81
52W Low
54.5
Volume
26,710
Avg. Volume
-
Mkt Cap
9.43B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.63
0.39
1.41
2.43
Expected EPS
2.429673
Actual EPS
N/A

Financials

-282.83%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
46.02MRevenue
-130.15MNet Income

Analyst Ratings

151.36Average Price Target
The highest estimate is 190.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
91%
Hold
9%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTGX. It's not an investment recommendation.
Microsoft
11
MSFT
NVIDIA
11
NVDA
Amazon
10
AMZN
Meta Platforms
9
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Arvinas
ARVN
Mkt Cap600.25M
Arvinas is involved in the development of protein degradation therapeutics, a field that overlaps with Protagonist's work on peptide-based therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on gene editing, competing in the broader biotech space for novel treatments, including cancer, which is a focus area for Protagonist.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Protagonist is active, such as cancer.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's focus on human therapeutics in areas including oncology and inflammation competes with Protagonist's therapeutic development.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences' extensive work in antiviral drugs and cancer therapies places it in direct competition with Protagonist's research and development efforts.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals' focus on developing monoclonal antibodies for a wide range of diseases competes with Protagonist's peptide-based therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals' work on treating serious diseases, including cancer, with novel drugs competes with Protagonist's development pipeline.

About

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Show more...
CEO
Dinesh V. Patel
Employees
141
Country
United States
ISIN
US74366E1029

Listings

STU
DE
PGF.STU
XNAS
US
PTGX
MX
MX
PTGX.MX
BOATS
BOATS
PTGX.BOATS

0 Comments

Share your thoughts

FAQ

What is Protagonist Therapeutics stock price today?▼
The current price of PTGX is $145.72 USD — it has decreased by -2.07% in the past 24 hours. Watch Protagonist Therapeutics stock price performance more closely on the chart.
What is Protagonist Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Protagonist Therapeutics stocks are traded under the ticker PTGX.
Is Protagonist Therapeutics stock price growing?▼
PTGX stock has risen by +0.96% compared to the previous week, the month change is a +6.12% rise, over the last year Protagonist Therapeutics has showed a +140.74% increase.
What is Protagonist Therapeutics market cap?▼
Today Protagonist Therapeutics has the market capitalization of 9.43B
When is the next Protagonist Therapeutics earnings date?▼
Protagonist Therapeutics is going to release the next earnings report on November 05, 2026.
What were Protagonist Therapeutics earnings last quarter?▼
PTGX earnings for the last quarter are 2.29 USD per share, whereas the estimation was 2.23 USD resulting in a +2.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protagonist Therapeutics revenue for the last year?▼
Protagonist Therapeutics revenue for the last year amounts to 46.02M USD.
What is Protagonist Therapeutics net income for the last year?▼
PTGX net income for the last year is -130.15M USD.
How many employees does Protagonist Therapeutics have?▼
As of September 05, 2026, the company has 141 employees.
In which sector is Protagonist Therapeutics located?▼
Protagonist Therapeutics operates in the Health & Wellness sector.
When did Protagonist Therapeutics complete a stock split?▼
Protagonist Therapeutics has not had any recent stock splits.
Where is Protagonist Therapeutics headquartered?▼
Protagonist Therapeutics is headquartered in NEWARK, United States.